Associated Papers
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.
Fischer NW et al.
Nature Communications, 2025
Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth.
Lv FL et al.
The Journal of Biological Chemistry, 2025
Predictive Molecular Biomarkers of Bladder Cancer Identified by Next-Generation Sequencing-Preliminary Data.
Myszka A et al.
Journal of Clinical Medicine, 2024
Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway.
Li H et al.
Npj Precision Oncology, 2024
Scalable approaches for generating, validating and incorporating data from high-throughput functional assays to improve clinical variant classification.
Padigepati SR et al.
Human Genetics, 2024
Mutations in the TP53, VEGFA, and CTH Genes as Key Molecular Markers for the Diagnosis of Glioblastoma.
Khalil SS et al.
Cureus, 2024
Cancer-derived C-terminus-extended p53 mutation confers dominant-negative effect on its wild-type counterpart.
Huang S et al.
Journal of Molecular Cell Biology, 2022
TP53_PROF: a machine learning model to predict impact of missense mutations in TP53.
Ben-Cohen G et al.
Briefings in Bioinformatics, 2022
Loss of peptidase D binding restores the tumor suppressor functions of oncogenic p53 mutants.
Yang L et al.
Communications Biology, 2021
Pathogenic genetic variants from highly connected cancer susceptibility genes confer the loss of structural stability.
Reza MN et al.
Scientific Reports, 2021
mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression.
Kon N et al.
Genes & Development, 2021
Targeted sequencing of FH-deficient uterine leiomyomas reveals biallelic inactivating somatic fumarase variants and allows characterization of missense variants.
Popp B et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2020
Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer.
Noguchi T et al.
Oncology Letters, 2020
From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion.
Quinn EA et al.
Cold Spring Harbor Molecular Case Studies, 2019
Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity.
Zheng S et al.
Cancer Research, 2017
Human EHMT2/G9a activates p53 through methylation-independent mechanism.
Rada M et al.
Oncogene, 2017
ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation.
Morton DJ et al.
Oncotarget, 2017
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S et al.
Oncotarget, 2016
Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.
Akiyama M et al.
International Journal of Hematology, 2015
The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain.
Laptenko O et al.
Molecular Cell, 2015
p53 degradation by a coronavirus papain-like protease suppresses type I interferon signaling.
Yuan L et al.
The Journal of Biological Chemistry, 2015
Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
Oh ET et al.
Investigational New Drugs, 2012
p53 requires an intact C-terminal domain for DNA binding and transactivation.
Kim H et al.
Journal of Molecular Biology, 2012
G9a and Glp methylate lysine 373 in the tumor suppressor p53.
Huang J et al.
The Journal of Biological Chemistry, 2010
p53 acetylation is crucial for its transcription-independent proapoptotic functions.
Yamaguchi H et al.
The Journal of Biological Chemistry, 2009
Kinetics of repression by modified p53 on the PDGF beta-receptor promoter.
Yang W et al.
International Journal of Cancer, 2008
An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2'-deoxycytidine treatment.
Wang H et al.
The Journal of Biological Chemistry, 2008
An acetylation switch in p53 mediates holo-TFIID recruitment.
Li AG et al.
Molecular Cell, 2007
The new bone biology: pathologic, molecular, and clinical correlates.
Cohen MM
American Journal of Medical Genetics. Part A, 2006
p53 stabilization and transactivation by a von Hippel-Lindau protein.
Roe JS et al.
Molecular Cell, 2006
Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).
Zhao Y et al.
Molecular and Cellular Biology, 2006
Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity.
Xirodimas DP et al.
Cell, 2004
The role of p53 deacetylation in p21Waf1 regulation by laminar flow.
Zeng L et al.
The Journal of Biological Chemistry, 2003